TRVI · Trevi Therapeutics, Inc. · Stock research

Current Thesis

The second breakout leg has stopped extending, and the re-rating has moved from the tape to the models. Trevi reported Q2 on 2026-08-06: net loss $17.8M (R&D $15.2M, G&A $5.4M), EPS -$0.11 against a -$0.10 consensus, and $318.9M in cash and marketable securities at June 30, with runway guided into 2030 "through potential FDA approval" in IPF-related chronic cough. In the eight sessions after that print, four firms marked targets up or reiterated above spot — Raymond James to $40 from $27 (Strong Buy, 2026-08-07), Cantor Fitzgerald to $30 from $25 (Overweight, 2026-08-07), Oppenheimer $25 (Outperform, 2026-08-07), Jones Trading $28 (Buy, 2026-08-14). What moved in those models is not efficacy: Raymond James lifted its assumed Haduvio annual price from $55,000 to $85,000 and layered in a non-IPF ILD program at 70% probability of success with $1.16B peak sales by 2035, for a candidate program that has not dosed a patient.

The tape did not follow. The 2026-08-14 close of $18.46 sits 5.3% under the $19.50 52-week high, with RSI(14) at 54.2 and a three-month return of +30%. That is a name digesting, with the last dated binary — the Q2 print — behind it and the next efficacy topline (OCEAN-2, 12-week dosing) guided to H2 2027. The narrative is maturing. The breakout structure from late June is intact and the sell-side is still above the price, but the leg that ran from the $16.12 old 52-week high to $19.07 on 2026-07-17 has not produced a new high in four weeks despite a clean print and a target-raise cluster. Accelerating narratives make new highs on that news flow.

Bullish and bearish views on Trevi Therapeutics, Inc.

The model's bull view on Trevi Therapeutics, Inc. (TRVI), in brief: Three trials now running or imminent, all initiated on guidance: OCEAN-1 Phase 3 in IPF-related chronic cough and the LAKE Phase 2b in refractory chronic cough both started in Q2 2026; OCEAN-2 is guided to start in Q3 2026 (Q2 release, 2026-08-06). The bear view: The catalyst calendar is empty of data for roughly twelve months. Both cases follow in full.

Bull Case

• Three trials now running or imminent, all initiated on guidance: OCEAN-1 Phase 3 in IPF-related chronic cough and the LAKE Phase 2b in refractory chronic cough both started in Q2 2026; OCEAN-2 is guided to start in Q3 2026 (Q2 release, 2026-08-06).
• Funded past both Phase 3 readouts: $318.9M cash and marketable securities at 2026-06-30 after $162.3M net proceeds from the April 2026 follow-on, against a $17.8M quarterly net loss (Q2 release, 2026-08-06).
• Indication count expanded: management guided an FDA alignment meeting on non-IPF ILD chronic cough in H2 2026 and the first study in that program in Q4 2026 — a second commercial pool on the same molecule (Q2 release; Raymond James note, 2026-08-07).
• The efficacy anchor is real and published: CORAL Phase 2b topline 2025-06-02, n=165, cut 24-hour cough frequency 60.2% at 108mg BID versus 16.9% on placebo, p<0.0001, published in JAMA in January 2026.
• No approved therapy exists for IPF-related chronic cough; Merck's gefapixant (P2X3) drew a CRL, leaving the kappa-agonist/mu-antagonist mechanism without a late-stage rival in the indication.
• Every published target since the print sits above the 2026-08-14 close of $18.46: $25, $28, $30, $40.

Bear Case

• The catalyst calendar is empty of data for roughly twelve months. OCEAN-2 topline is guided H2 2027; OCEAN-1 reads H1 2028. Everything between is enrollment updates and expense lines.
• Price has stopped rewarding good news. The 2026-07-17 session closed $19.07 on 8.3M shares; four target raises later, the 2026-08-14 close is $18.46 and the 52-week high stands at $19.50.
• The Raymond James $40 rests on an assumption change ($55,000 → $85,000 annual price) and a 70% success probability assigned to an unstarted program. Target expansion of that kind is reversible without any clinical event.
• Issuance capacity is armed: shareholders doubled authorized shares from 200M to 400M on 2026-06-03, and the last deal cleared at $13.00 for 11.6M shares.
• The small-cap asymmetry is spent. Market capitalisation was $2.71B on 141.98M shares at the 2026-07-17 close of $19.07, against a $6.55 52-week low — the tape already prices a substantial share of Phase 3 success.
• Q2 EPS of -$0.11 missed the -$0.10 consensus. Immaterial on its own for a pre-revenue company, but burn steps up with three trials running in parallel and a fourth program starting in Q4.

Setup & Price Structure

• Reference close 2026-08-14: $18.46. Distance from the $19.50 52-week high: -5.3%. RSI(14) 54.2 — neutral, cooled from the July expansion. Three-month return +30%.
• The structure under the name is the late-June breakout over the prior $16.12 52-week high, and the $18.17 June all-time high that became the shelf. The July move to a $19.07 close extended it; the four weeks since have gone sideways beneath the high rather than rolling over.
• Below the shelf sits the $13–16 post-offering range the name occupied from the April deal at $13.00 until late June. A weekly close below $16 puts it back inside that range.
• Crowding observables, stated plainly: four analyst actions clustered 2026-08-07 to 2026-08-14, all above spot, all after the move; the earnings binary is behind rather than ahead, so nothing dated forces repricing in either direction; authorized share count doubled ten weeks ago; the last capital raise was priced 30% below the current tape. No insider transaction data is cited here because none was verified for this window.

Catalyst Calendar (next 30 days)

• ~2026-09-30 (est.) — OCEAN-2 Phase 3 initiation disclosure, guided for Q3 2026. Slippage past quarter-end would be the first missed operational guide of the program.
• ~2026-11-12 (est.) — Q3 2026 results (Q3 2025 was reported 2025-11-13). Confirms burn trajectory and whether OCEAN-2 started on time.
• Q4 2026 (est.) — first non-IPF ILD study initiation, following the FDA alignment meeting guided for H2 2026.
• H2 2027 — OCEAN-2 topline (12-week dosing). H1 2028 — OCEAN-1 topline (52-week dosing, primary endpoint at 24 weeks).

Elapsed catalysts

• No dated company event falls inside the window. Q2 reported 2026-08-06; the company's two announced August conference appearances fall on or before mid-August and have elapsed. (passed 20d ago)

What Would Change Our Mind

The load-bearing structure is the June shelf over the old $16.12 52-week high; the entire second leg stands on it. A weekly close below $16 surrenders that shelf and returns the name to the $13–16 range it left in late June — that is the gradeable break. Operationally, the thesis weakens if OCEAN-2 is not disclosed as initiated by the Q3 print, since Q3 2026 initiation is the one near-dated commitment management has made. A prospectus supplement or ATM filing into this strength, despite the guided 2030 runway, would say the 200M→400M authorization increase was for use rather than housekeeping. An 8-K disclosing a clinical hold, a protocol amendment or an SAE cluster in an opioid-derived molecule ends the discussion regardless of price. In the other direction, the maturing read would flip back toward accelerating on sustained closes above the $19.50 52-week high accompanied by an actual event — FDA alignment on non-IPF ILD, or OCEAN-2 dosing — rather than another target raise.

Correlation Notes

• High beta to XBI: a sector drawdown can carry the name below the June shelf with no company-specific news, and sector-driven strength here carries no information about Haduvio.
• Long-duration, pre-revenue clinical asset — sensitive to the rate path in the same way as the rest of small/mid-cap biotech, with no earnings stream to anchor valuation.
• Indication-adjacent read-across: any late-stage entrant in IPF or non-IPF ILD cough, or a competitor regulatory action, prices directly into the competitive-void argument that supports the current multiple.
• Sell-side dispersion is itself a correlated variable: targets from $25 to $40 issued within eight sessions mean the name trades on model assumptions (price per patient, probability of success) that move together when one firm revises.